Suppr超能文献

新型冠状病毒肺炎疫苗的安全性和有效性:叙述性综述。

Safety & effectiveness of COVID-19 vaccines: A narrative review.

机构信息

Department of Public Health, Post-graduate School of Occupational Medicine, Catholic University of the Sacred Heart, Rome, Italy.

Independent Researcher, Kagawa-Ken, Japan.

出版信息

Indian J Med Res. 2022 Jan;155(1):91-104. doi: 10.4103/ijmr.IJMR_474_21.

Abstract

There are currently eight vaccines against SARS-CoV-2 that have received Emergency Use Authorization by the WHO that can offer some protection to the world's population during the COVID-19 pandemic. Though research is being published all over the world, public health officials, policymakers and governments are collecting evidence-based information to establish the public health policies. Unfortunately, continued international travel, violations of lockdowns and social distancing, the lack of mask use, the emergence of mutant strains of the virus and lower adherence by a sector of the global population that remains sceptical of the protection offered by vaccines, or about any risks associated with vaccines, hamper these efforts. Here we examine the literature on the efficacy, effectiveness and safety of COVID-19 vaccines, with an emphasis on select categories of individuals and against new SARS-CoV-2 strains. The literature shows that these eight vaccines are highly effective in protecting the population from severe disease and death, but there are some issues concerning safety and adverse effects. Further, booster shots and variant-specific vaccines would also be required.

摘要

目前,世界卫生组织已授权使用 8 种针对 SARS-CoV-2 的疫苗,这些疫苗在 COVID-19 大流行期间可为世界人口提供一定程度的保护。虽然世界各地都在发表研究成果,但公共卫生官员、政策制定者和政府正在收集基于证据的信息,以制定公共卫生政策。不幸的是,持续的国际旅行、违反封锁和社交距离措施、缺乏口罩使用、病毒变异株的出现以及全球部分对疫苗提供的保护或与疫苗相关的任何风险持怀疑态度的人群的较低疫苗接种率,都妨碍了这些努力。在这里,我们研究了 COVID-19 疫苗的疗效、有效性和安全性的文献,重点关注特定类别的人群和针对新的 SARS-CoV-2 菌株。文献表明,这 8 种疫苗在保护人群免受严重疾病和死亡方面非常有效,但在安全性和不良反应方面存在一些问题。此外,还需要加强针和针对变异株的疫苗。

相似文献

1
Safety & effectiveness of COVID-19 vaccines: A narrative review.
Indian J Med Res. 2022 Jan;155(1):91-104. doi: 10.4103/ijmr.IJMR_474_21.
3
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1-16. doi: 10.1080/14760584.2023.2143347. Epub 2022 Nov 11.
4
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
5
COVID-19 vaccines: concerns beyond protective efficacy and safety.
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
6
Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.
Int J Biol Sci. 2022 Jul 11;18(12):4642-4647. doi: 10.7150/ijbs.72424. eCollection 2022.
8
A review of the safety and efficacy of current COVID-19 vaccines.
Front Med. 2022 Feb;16(1):39-55. doi: 10.1007/s11684-021-0893-y. Epub 2022 Feb 3.
9
[Vaccination contre le SARS-CoV-2, le Graal ?].
Rev Prat. 2022 May;72(5):517-522.
10
[SARS-CoV-2 vaccines].
Ugeskr Laeger. 2021 Mar 8;183(10).

引用本文的文献

1
The complexities of 'trust' in the context of COVID-19 vaccination choices among Black women in Alameda County, CA.
Crit Public Health. 2025;35(1). doi: 10.1080/09581596.2025.2486498. Epub 2025 Apr 12.
4
In-hospital mortality among hospitalized COVID-19 patients in a tertiary care hospital in Dhaka City: a retrospective cohort study.
Front Med (Lausanne). 2025 May 20;12:1571865. doi: 10.3389/fmed.2025.1571865. eCollection 2025.
5
Clinical profile of alcohol dependent paintents according to Lesch Typology one year after the Covid-19 pandemic-comparative study.
PLoS One. 2025 May 23;20(5):e0324851. doi: 10.1371/journal.pone.0324851. eCollection 2025.
7
A meta-analysis on the effectiveness of serotype O foot-and-mouth disease vaccines.
Sci Rep. 2025 May 2;15(1):15381. doi: 10.1038/s41598-025-99518-3.
8
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.

本文引用的文献

1
Heavily mutated Omicron variant puts scientists on alert.
Nature. 2021 Dec;600(7887):21. doi: 10.1038/d41586-021-03552-w.
2
SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence.
Lancet Reg Health Am. 2022 Feb;6:100112. doi: 10.1016/j.lana.2021.100112. Epub 2021 Nov 18.
4
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
7
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验